Loading...
Pexidartinib: First Approval
Pexidartinib (TURALIO™) is an orally administered small molecule tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutati...
Na minha lista:
| Udgivet i: | Drugs |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7044138/ https://ncbi.nlm.nih.gov/pubmed/31602563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-019-01210-0 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|